Clinical Trials Browser

INDUSTRY × Carcinoma in Situ × 1 year × Clear all

NCT06833073 2026-05-28

INTerpath-011

Phase 2 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT05951179 2026-05-18

ADVANCED-2

Phase 2 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT04752722 2026-04-30

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Phase 1/2 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT07283835 2026-04-23

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Phase 2 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT07480356 2026-03-18

ADVANCED-3

Phase 3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Neoplasms

NCT04452591 2026-03-16

BOND-003

Phase 3 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT06022029 2025-12-24

ON-5001

Phase 1 Recruiting

BreastDermatologicGenitourinaryGynecologicHead & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Bites and Stings, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma in Situ, Uterine Cervical Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Skin Neoplasms, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Triple Negative Breast Neoplasms

NCT05014139 2025-11-20

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Phase 1 Terminated

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT04368247 2025-08-07

Skin Fluorescent Imaging (SFI) System in Patients With Nevi

Carcinoma in Situ, Dysplastic Nevus Syndrome, Nevus

NCT07092007 2025-07-29

NWRD09 for HPV-16 Related Intraepithelial Neoplasia and Cervical Cancer

Phase NA Recruiting

Carcinoma in Situ, Uterine Cervical Neoplasms